Erste Asset Management’s Acceleron Pharma XLRN Stock Holding History

Erste Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-21,600	Closed	-$3.79M	–	565
2021 Q3	$3.79M	Hold	21,600	–	–	0.08%	229
2021 Q2	$2.69M	Hold	21,600	–	–	0.05%	261
2021 Q1	$2.87M	Buy	21,600 +5,500	+34%	+$710K	0.07%	231
2020 Q4	$2.02M	Buy	16,100 +200	+1%	+$23.5K	0.06%	263
2020 Q3	$1.8M	Hold	15,900	–	–	0.06%	261
2020 Q2	$1.53M	Hold	15,900	–	–	0.06%	259
2020 Q1	$1.36M	Sell	15,900 -11,000	-41%	-$855K	0.08%	223
2019 Q4	$1.38M	Hold	26,900	–	–	0.06%	248
2019 Q3	$1.09M	Hold	26,900	–	–	0.06%	254
2019 Q2	$1.1M	Hold	26,900	–	–	0.06%	245
2019 Q1	$1.21M	Sell	26,900 -3,000	-10%	-$132K	0.07%	229
2018 Q4	$1.27M	Buy	+29,900	New	+$1.49M	0.09%	213

Erste Asset Management's XLRN Position: Q4 2021 in Review

Erste Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 21,600 shares — an estimated $3.79M sold.

Erste Asset Management first reported a position in XLRN in Q4 2018 and held it in 12 quarters. The position peaked at $3.79M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Erste Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Erste Asset Management sold 21,600 Acceleron Pharma shares in Q4 2021, an estimated $3.79M.
Erste Asset Management first reported a position in Acceleron Pharma in Q4 2018 and held it in 12 quarters.
Erste Asset Management's Acceleron Pharma position peaked at $3.79M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Erste Asset Management's 13F filing for Q4 2021, filed 25 Nov 2024.